Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Methotrexate in Children With Residual Ependymoma
NCT00287924Phase 2Unknown
- Sponsor
- Children's Cancer and Leukaemia Group
- Start
- Mar 2005
- Primary completion
- Mar 2010
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of methotrexate in ependymoma, sponsored by Children's Cancer and Leukaemia Group. Primary endpoint: Activity of high-dose methotrexate at 6 weeks. Status: unknown.
02
Drugs
methotrexate
03
Conditions
ependymoma
Beyond the preview
Go deeper on NCT00287924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00287924.